NZ707389A - Process for preparing bile acid derivatives - Google Patents

Process for preparing bile acid derivatives

Info

Publication number
NZ707389A
NZ707389A NZ707389A NZ70738913A NZ707389A NZ 707389 A NZ707389 A NZ 707389A NZ 707389 A NZ707389 A NZ 707389A NZ 70738913 A NZ70738913 A NZ 70738913A NZ 707389 A NZ707389 A NZ 707389A
Authority
NZ
New Zealand
Prior art keywords
acid derivatives
bile acid
formula
preparing bile
preparing
Prior art date
Application number
NZ707389A
Other languages
English (en)
Inventor
Roberto Pellicciari
Antimo Gioiello
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Priority to NZ745013A priority Critical patent/NZ745013A/en
Publication of NZ707389A publication Critical patent/NZ707389A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ707389A 2012-10-26 2013-10-25 Process for preparing bile acid derivatives NZ707389A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ745013A NZ745013A (en) 2012-10-26 2013-10-25 Process for preparing bile acid derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261718966P 2012-10-26 2012-10-26
PCT/US2013/066917 WO2014066819A1 (en) 2012-10-26 2013-10-25 Process for preparing bile acid derivatives

Publications (1)

Publication Number Publication Date
NZ707389A true NZ707389A (en) 2018-08-31

Family

ID=50545344

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ745013A NZ745013A (en) 2012-10-26 2013-10-25 Process for preparing bile acid derivatives
NZ707389A NZ707389A (en) 2012-10-26 2013-10-25 Process for preparing bile acid derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ745013A NZ745013A (en) 2012-10-26 2013-10-25 Process for preparing bile acid derivatives

Country Status (22)

Country Link
US (2) US9777038B2 (enExample)
EP (1) EP2912013B1 (enExample)
JP (1) JP6272888B2 (enExample)
KR (1) KR102068381B1 (enExample)
CN (2) CN108250264A (enExample)
AU (1) AU2013334122B2 (enExample)
BR (1) BR112015009395A2 (enExample)
CA (1) CA2889592A1 (enExample)
CY (1) CY1119731T1 (enExample)
DK (1) DK2912013T3 (enExample)
ES (1) ES2655034T3 (enExample)
HK (1) HK1253301A1 (enExample)
HU (1) HUE036887T2 (enExample)
IL (1) IL238454B (enExample)
MX (1) MX361653B (enExample)
NO (1) NO2968302T3 (enExample)
NZ (2) NZ745013A (enExample)
PL (1) PL2912013T3 (enExample)
PT (1) PT2912013T (enExample)
SG (1) SG11201503247UA (enExample)
SM (1) SMT201700602T1 (enExample)
WO (1) WO2014066819A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108250264A (zh) 2012-10-26 2018-07-06 英特塞普特医药品公司 制备胆汁酸衍生物的方法
LT3149019T (lt) 2014-05-29 2020-02-25 Bar Pharmaceuticals S.R.L. Cholano dariniai, skirti naudoti fxr ir tgr5/gpbar1 medijuojamų ligų gydymui ir (arba) prevencijai
EA033445B1 (ru) 2014-11-19 2019-10-31 Nzp Uk Ltd 5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
WO2016079517A1 (en) 2014-11-19 2016-05-26 Dextra Laboratories Limited 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
EA033603B1 (ru) 2014-11-19 2019-11-08 Nzp Uk Ltd 6-альфа-алкил-6,7-дионовые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
WO2016079519A1 (en) 2014-11-19 2016-05-26 Dextra Laboratories Limited 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators
CN104672290B (zh) * 2015-01-05 2017-06-06 北京普禄德医药科技有限公司 一种用于预防或治疗fxr‑介导的疾病的药物及其制备方法和用途
EA036404B1 (ru) 2015-02-06 2020-11-06 Интерсепт Фармасьютикалз, Инк. Фармацевтические композиции для комбинированной терапии
KR20180052756A (ko) * 2015-09-24 2018-05-18 인터셉트 파마슈티컬즈, 인크. 담즙산 유도체 제조를 위한 방법 및 중간체
WO2017079062A1 (en) * 2015-11-06 2017-05-11 Intercept Pharmaceuticals, Inc. Methods for the preparation of obeticholic acid and derivatives thereof
US20200262865A1 (en) * 2016-02-15 2020-08-20 Alexander Khoruts Compositions and methods for treating clostridium associated diseases
KR102377338B1 (ko) 2016-04-13 2022-03-21 인터셉트 파마슈티컬즈, 인크. 암의 치료 방법
TW201738254A (zh) * 2016-04-19 2017-11-01 英特賽普醫藥品公司 奧貝膽酸及其衍生物之製備方法
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
BR112019006242A2 (pt) * 2016-09-30 2019-06-18 Intercept Pharmaceuticals Inc formas cristalinas de um derivado de ácido biliar
AU2018307611A1 (en) 2017-07-24 2020-02-06 Intercept Pharmaceuticals, Inc. Isotopically labeled bile acid derivatives
EP3660030A4 (en) * 2017-07-26 2021-04-21 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. METHOD OF MANUFACTURING STEROID-DERIVATIVE FXR AGONISTS
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CA3142358A1 (en) 2019-05-30 2020-12-03 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
WO2021071837A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
EP4153589A4 (en) 2020-05-19 2024-06-12 Kallyope, Inc. AMPK ACTIVATORS
WO2021263039A1 (en) 2020-06-26 2021-12-30 Kallyope, Inc. Ampk activators
JP7583398B2 (ja) 2020-09-18 2024-11-14 ソウル大学校産学協力団 タウロデオキシコール酸ナトリウムの大量生産方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216015A (en) * 1991-02-05 1993-06-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having hypocholesterolemic properties
DE60205891T2 (de) 2001-03-12 2006-06-22 Intercept Pharmaceuticals, Inc. Steroide als agonisten für fxr
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
PL2040713T3 (pl) * 2006-06-27 2014-11-28 Intercept Pharmaceuticals Inc Pochodne kwasów żółciowych jako ligandy FXR do zapobiegania lub leczenia chorób lub stanów, w których pośredniczy FXR
EP2303026B1 (en) * 2008-06-17 2020-09-09 Brigham Young University Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods
US8796249B2 (en) * 2008-07-30 2014-08-05 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
ES2774368T3 (es) * 2008-11-19 2020-07-20 Intercept Pharmaceuticals Inc Moduladores de TGR5 y métodos de uso de los mismos
CN108250264A (zh) 2012-10-26 2018-07-06 英特塞普特医药品公司 制备胆汁酸衍生物的方法

Also Published As

Publication number Publication date
ES2655034T3 (es) 2018-02-16
HK1253301A1 (zh) 2019-06-14
BR112015009395A2 (pt) 2017-07-04
SG11201503247UA (en) 2015-06-29
NO2968302T3 (enExample) 2018-02-03
AU2013334122A1 (en) 2015-05-14
MX361653B (es) 2018-12-13
HK1214239A1 (zh) 2016-07-22
HUE036887T2 (hu) 2018-08-28
DK2912013T3 (en) 2018-01-15
US20180079776A1 (en) 2018-03-22
CN105102425A (zh) 2015-11-25
AU2013334122B2 (en) 2017-11-02
KR20150074062A (ko) 2015-07-01
EP2912013A4 (en) 2016-06-01
PL2912013T3 (pl) 2018-05-30
US10202414B2 (en) 2019-02-12
SMT201700602T1 (it) 2018-03-08
IL238454A0 (en) 2015-06-30
KR102068381B1 (ko) 2020-01-20
WO2014066819A1 (en) 2014-05-01
US9777038B2 (en) 2017-10-03
PT2912013T (pt) 2018-01-03
CN108250264A (zh) 2018-07-06
US20150291653A1 (en) 2015-10-15
CY1119731T1 (el) 2018-06-27
JP2015533852A (ja) 2015-11-26
EP2912013A1 (en) 2015-09-02
JP6272888B2 (ja) 2018-01-31
CN105102425B (zh) 2018-04-10
MX2015005286A (es) 2015-10-29
EP2912013B1 (en) 2017-10-11
IL238454B (en) 2018-11-29
NZ745013A (en) 2019-08-30
CA2889592A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
NZ707389A (en) Process for preparing bile acid derivatives
IN2012DN02751A (enExample)
EA033513B1 (ru) Способы получения хинолиновых соединений и фармацевтических композиций, содержащих такие соединения
IN2015DN00598A (enExample)
MD20180040A2 (ro) Inhibitori ai virusului hepatic C
PH12015501226A1 (en) Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing the same
PH12015500334A1 (en) Azaindole carboxylic acid amides and azaindole thiocarboxylic acid amides for use as insecticides and acaricides
IN2014CN04449A (enExample)
JO3318B1 (ar) مثبطات bace
PH12014502492A1 (en) Pyrazole compounds as sglt1 inhibitors
MX2012001411A (es) Proceso para la preparacion de derivados de acido 1-(2-halobifenil-4-il)-ciclopropanocarboxilico.
PH12015501146A1 (en) Hydantoin derivative
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
WO2012140490A3 (en) Processes for preparing pitavastatin calcium
MX2013000294A (es) Intermedios y procedimiento de preparación de un inhibidor específico de la trombina.
MX350430B (es) Proceso para preparar compuestos acido 4-amino-5-bifenil-4-il-2-hi droximetil-2-metil-pentanoico.
IN2015DN00950A (enExample)
MX364529B (es) Nuevos ligandos del receptor de estrógeno.
SG10201901578UA (en) Processes for the preparation of pyrimidinylcyclopentane compounds
MX2014009084A (es) Derivados de pirimidooxazocina como inhibidores de mtor.
MX361998B (es) Procedimiento de preparacion de derivados de acido 4-haloalquil-3-mercapto-2 sustituido-hidroxibenzoico.
IN2012DN02000A (enExample)
WO2012150183A8 (en) Crystalline sodium salt of an hiv integrase inhibitor
WO2014024203A8 (en) An improved process for - the preparation of dexmethylphenidate hydrochloride.

Legal Events

Date Code Title Description
PSEA Patent sealed
S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 OCT 2020 BY COMPUTER PACKAGES INC

Effective date: 20191001

S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 OCT 2021 BY COMPUTER PACKAGES INC

Effective date: 20201001

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 OCT 2022 BY COMPUTER PACKAGES INC

Effective date: 20210930

LAPS Patent lapsed